You want to apply the patch to a clean, dry, hairless area of skin
Tirzepatide for Sustained Weight Reduction in Adults with Obesity (SURMOUNT-4)
While we do not process insurance claims directly, we can provide you with an itemized receipt to submit to your insurance for reimbursement
IP portfolio composition (approximate): Composition-of-matter patents: expired 2016 (US) and 2018 (EU) Manufacturing process patents: extended effective protection through 2022 and beyond in some jurisdictions Formulation patents: citrate-free high-concentration formulation, enabling the Humira CF transition Device patents: proprietary auto-injector design Method-of-use patents: spanning 14 approved indications including RA, Crohns disease, psoriasis, uveitis, and pediatric extensions IP valuation framework: At peak, Humiras patent portfolio represented approximately $15-18 billion in net present value of protected cash flows (using a 10% discount rate, a 75% probability of litigation success based on historical BPCIA outcomes, and a 3-year median delay from patent challenge to market entry)
Clinical response is reassessed after eight to twelve weeks, with upward titration permitted in 0.0125- to 0.025-mg/day increments until satisfactory relief is achieved, not exceeding 0.1 mg/day for most indications
For example, in a 68-week clinical trial, semaglutide users experienced an average weight loss of 15.8%, with 86% of participants achieving clinically meaningful results
